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Liver transplantation (LT) candidates today are increasingly older, have greater medical acuity, and have more
cardiovascular comorbidities than ever before. Steadily rising model for end-stage liver disease (MELD) scores at
the time of transplant, resulting from high organ demand, reflect the escalating risk profiles of LT candidates. In
addition to advanced age and the presence of comorbidities, there are specific cardiovascular responses in cir-
rhosis that can be detrimental to the LT candidate. Patients with cirrhosis requiring LT usually demonstrate in-
creased cardiac output and a compromised ventricular response to stress, a condition termed cirrhotic cardiomy-
opathy. These cardiac disturbances are likely mediated by decreased beta-agonist transduction, increased
circulating inflammatory mediators with cardiodepressant properties, and repolarization changes. Low systemic
vascular resistance and bradycardia are also commonly seen in cirrhosis and can be aggravated by beta-blocker
use. These physiologic changes all contribute to the potential for cardiovascular complications, particularly with
the altered hemodynamic stresses that LT patients face in the immediate post-operative period. Post-transplant
reperfusion may result in cardiac death due to a multitude of causes, including arrhythmia, acute heart failure,
and myocardial infarction. Recognizing the hemodynamic challenges encountered by LT patients in the perioper-
ative period and how these responses can be exacerbated by underlying cardiac pathology is critical in develop-
ing recommendations for the pre-operative risk assessment and management of these patients. The following
provides a review of the cardiovascular challenges in LT candidates, as well as evidence-based recommenda-
tions for their evaluation and management. (J Am Coll Cardiol 2011;58:223–31) © 2011 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.03.026Liver transplantation (LT) candidates today are older, have
greater medical acuity, and have more comorbidities, in-
cluding cardiovascular disease, than ever before (1). Steadily
rising model for end-stage liver disease (MELD) scores at
the time of transplant, resulting from high organ demand,
reflect the escalating risk profiles of LT candidates (1). In
addition to advanced age and the presence of comorbidities,
there are specific cardiovascular responses in end-stage liver
From the *Department of Medicine, Division of Cardiology, Northwestern Univer-
sity Feinberg School of Medicine, Chicago, Illinois; †Division of Cardiology,
Cardiovascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Penn-
sylvania; ‡Department of Surgery, Division of Transplantation, Northwestern Uni-
versity Feinberg School of Medicine, Chicago, Illinois; §Department of Anesthesi-
ology, Northwestern University Feinberg School of Medicine, Chicago, Illinois;
Department of Medicine, Division of Gastroenterology, University of California San
Francisco, San Francisco, California; and the ¶Center for Cardiovascular Innovation,
Northwestern University, Feinberg School of Medicine, Chicago, Illinois. Dr.
Gheorghiade is a consultant for Abbott Laboratories, Astellas, AstraZeneca, Bayer
Schering Pharma AG, CorThera Inc., Cytokinetics Inc., DebioPharm S.A., Er-
rekappa Terapeuitici, GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck,
Novartis Pharma AG, Otsuka Pharmaceuticals, Pericor Therapeutics, Protein Design
Laboratories, Sanofi-Aventis, Sigma Tau, and Solvay Pharmaceuticals. All other
authors have reported that they have no relationships to disclose.
Manuscript received November 4, 2010; revised manuscript received March 8,
2011, accepted March 21, 2011.disease (ESLD) that can be detrimental to the LT candi-
date. Patients with ESLD requiring LT usually demon-
strate increased cardiac output and a compromised ventric-
ular response to stress, a condition termed cirrhotic
cardiomyopathy. These cardiac disturbances are likely me-
diated by decreased beta-agonist transduction, increased
circulating inflammatory mediators with cardiodepressant
properties, and repolarization changes (2–7). Low systemic
vascular resistance and bradycardia are also commonly seen
in cirrhosis and can be aggravated by beta-blocker use.
These physiologic changes all contribute to the potential
for cardiovascular complications, particularly with the
altered hemodynamic stresses that LT patients face
post-operatively.
The hemodynamic stress of LT is greatest after reperfu-
sion of the transplanted liver and is characterized by a
sudden increase in pre-load. In the setting of a cardiomy-
opathy, elevation in pulmonary capillary wedge pressure
and/or reduction in mean arterial pressure can herald
profound post-reperfusion hemodynamic instability and
hepatic congestion. Post-transplant reperfusion may result
in cardiac death due to a multitude of causes, including
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and myocardial infarction (8,9).
Recognizing the hemodynamic
challenges encountered by LT pa-
tients post-operatively, and how
these responses can be exacerbated
by underlying cardiac pathology, is
critical in developing recommen-
dations for the pre-operative risk
assessment and management of
these patients. The following pro-
vides a review of the cardiovascular
challenges presented by ESLD pa-
tients, as well as evidence-based
recommendations for their evalua-
tion and management.
Coronary Artery Disease
Patients with established coro-
nary artery disease (CAD) who
undergo LT have worse out-
comes than do patients without
CAD (10,11). A 1-year mortality
rate of approximately 40% has
been reported after LT for pa-
tients with CAD (12). Coronary
atherosclerosis is common in this
population and often goes undi-
agnosed. In a study of 161 LT
candidates at risk for CAD re-
ferred for coronary angiography,
25% of patients had at least 1
moderate or severe (50%) cor-
onary stenosis. Obstructive CAD was most common among
patients with 2 traditional cardiac risk factors (13). Non-
obstructive lesions (coronary artery stenosis 50%) are
unlikely to be detected by stress imaging, but can also be
responsible for acute coronary syndromes (unstable angina,
myocardial infarction, or sudden cardiac death) (14,15). In
fact, it is thought that acute coronary syndromes often result
from rupture of coronary plaques with 50% stenosis
(16,17).
Traditional coronary risk factors (Table 1) remain impor-
tant for pre-operative risk stratification in patients with
ESLD. Diabetes mellitus (DM) and age 50 years are
particularly predictive of post-operative ischemic complica-
tions (12,18–21). By 1 estimate, 5-year survival is approx-
imately 40% lower among persons with insulin-dependent
DM or known CAD than among persons without these
conditions (22). The LT recipients display higher Framing-
ham risk scores than age- and sex-matched non-LT patients
(23). The relative predictive value of Framingham risk score
for cardiac events is an area of ongoing research. Although
1 retrospective cohort study did report a low incidence of
Abbreviations
and Acronyms
CAD  coronary artery
disease
CT  computed
tomography
DM  diabetes mellitus
DSE  dobutamine stress
echocardiography
ESLD  end-stage liver
disease
HPS  hepatopulmonary
syndrome
LT  liver transplantation
LVOTO  left ventricular
outflow tract obstruction
MELD  model for end-
stage liver disease
mPAP  mean pulmonary
arterial pressure
NPV  negative predictive
value
PFO  patent foramen
ovale
POPH  portopulmonary
hypertension
QTc  corrected QT
interval
SPECT  single-positron
emission computed
tomography
TTE  transthoracic
echocardiographyischemic events at 4-year follow-up, most analyses reveal rhigher event rates than predicted by Framingham scores,
possibly reflecting more comorbidities or a greater sever-
ity of illness compared to patients without ESLD (23).
The presence of other traditional risk factors, specifically
hypertension and hyperlipidemia, has also been shown to
be independently associated with worse outcomes after
LT (24).
Nontraditional coronary risk factors have also been stud-
ied. One retrospective case-control study showed an in-
creased prevalence of CAD among patients with cirrhosis
due to nonalcoholic steatohepatitis. In this study, patients
with nonalcoholic steatohepatitis cirrhosis were more likely
to have traditional CAD risk factors and the metabolic
syndrome than were patients with other etiologies of cir-
rhosis (25). Whether nonalcoholic steatohepatitis cirrhosis
is an independent CAD risk factor with incremental pre-
dictive value over these traditional risk factors remains to be
determined (26–28). Coronary calcium is also strongly
associated with traditional CAD risk factors in the cirrhotic
population (29). In addition, concomitant renal dysfunction
in the setting of ESLD is associated with increased cardio-
vascular risk (30). Although elevated C-reactive protein is
associated with increased cardiovascular events, it has only
been studied post-operatively in the ESLD population (31).
C-reactive protein appears to peak and slowly fall within 1
week after LT, and delayed elevations may indicate inflam-
matory complications such as post-operative infection or
rejection (32).
The significant hemodynamic stress of LT and preva-
lence of underlying CAD in ESLD patients warrants a
routine pre-operative cardiac assessment (Table 1). How-
ever, noninvasive functional testing for ischemia may have
limited predictive value for obstructive CAD in this popu-
lation (Table 1). Most patients cannot undergo exercise
testing. Dobutamine stress echocardiography (DSE) has
been shown to have a poor sensitivity and a low negative
predictive value (NPV) among LT candidates, possibly
secondary to an inability to achieve target heart rate and
peak double product (heart rate multiplied by blood pres-
sure). A retrospective study of 105 ESLD patients who
underwent both DSE and coronary angiography found
DSE to have a sensitivity of 13% and NPV of 75% for
obstructive CAD (33). Although there are limited data on
he predictive value of DSE for post-operative cardiovascu-
ar events, 1 study suggests that a low peak double product
nd chronotropic incompetence are predictive of cardiovas-
ular events (34). The negative predictive value for DSE in
T candidates has been estimated to be 85% in some
tudies (35,36). Recently, a large retrospective study of 400
T patients examined the association between pre-operative
SE and adverse cardiac events (death/nonfatal myocardial
nfarction) at 30 days. They found that DSE had a fairly
trong NPV of 89%, but a positive predictive value of only
7% for the identification of post-transplant cardiac events
37). However, the majority of patients in this study had
elatively low MELD scores (15); thus, these findings
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higher MELD scores.
Similarly, it has been suggested that the predictive value
of nuclear single-photon emission computed tomography
(SPECT) stress imaging is limited by the chronic vasodi-
latory state exhibited by patients with ESLD (38). In a
recent prospective study, the specificity of abnormal
SPECT findings for obstructive CAD by coronary angiog-
raphy was only 61% (39). This low specificity may be due to
the fact that ESLD patients often exhibit impaired coronary
flow reserve, which is typically the result of coronary
microvascular dysfunction rather than epicardial lesions
(40,41). One retrospective review of 339 patients found an
excellent NPV of 99% for SPECT in patients with cirrhosis,
but this was in a low-risk cohort (42).
Therefore, on the basis of available data, either an
bnormal noninvasive test or a high pre-test probability of
AD should prompt consideration for coronary angiogra-
hy (Table 1). Obstructive CAD not amenable to revascu-
arization (either percutaneous or surgical) can form the
asis for denial of LT in some centers (43). However,
uccessful coronary revascularization for obstructive CAD
as been used before LT in otherwise suitable candidates
44,45). In general, drug-eluting stents are not recom-
ended in this population because of the requirement for
rolonged dual antiplatelet therapy and increased risk of
leeding.
Coronary angiography has been associated with an
cceptable safety profile in LT candidates, who often
Pre-Operative Cardiovascular Assessment and ManagementTable 1 Pre-Operative Cardiovascular Assessment and Manage
Potential CV Pathophysiology Diagnostic Findings and Test Operating Ch
Low HR Noninvasive stress imaging*
Chronic vasodilatory state
Low SVR, low BP
Low sensitivity, low NPV of DSE (inability to rea
HR  BP)
Low PPV, false positives of SPECT (decreased
reserve)
High cardiac output
LVH
Systolic/diastolic dysfunction
LVOTO
Echocardiography
Subclinical cardiomyopathy (LVH)
Inducible LVOTO on DSE
Early, reversible systolic dysfunction post-opera
Portopulmonary hypertension
(pulmonary arterial HTN)
Echocardiography: elevated right-sided and pu
pressures. Right-side heart catheterization:
25 mm Hg, PVR 3 Wood units in the se
PCWP 15 mm Hg
Pericardial effusions Echocardiography: potentially decreased PPV f
in setting of POPH  elevated right-sided pr
Prolonged QTc interval Electrocardiography: long QTc, potentially reve
differences in QTc abolished
Pre-existing intracardiac shunt Echocardiography: PFO or other intracardiac sh
*Utility of noninvasive testing for coronary artery disease (CAD) detection in liver transplantation
dobutamine stress echocardiography (DSE)  22%/75%, respectively (Harinstein et al. [33]), 33
single-photon emission computed tomography (SPECT)  22%/77%, respectively (Davidson et
years/female 55 years), hypercholesterolemia, hypertension, tobacco use, and family history of
BP  blood pressure; DM  diabetes mellitus; HF  heart failure; HTN  hypertension; LVH  l
value; PAP  pulmonary arterial pressure; PASP  pulmonary artery systolic pressure; PCWP  pu
PVR  pulmonary vascular resistance; QTc  corrected QT interval; RHC  right heart catheterizaave coagulopathies that render them at higher risk for tleeding complications, or concomitant renal dysfunction
hat increases the risk of contrast-induced nephropathy
46,47). A transradial approach to invasive angiography may
rove useful in the ESLD population to further reduce
leeding complications (48). Cardiac computed tomography
CT) angiography is emerging as an attractive noninvasive
lternative to invasive coronary angiography for the assess-
ent of CAD in select LT candidates (49). Favorable
atient features for cardiac CT angiography include normal
enal function, a nontachycardic regular cardiac rhythm,
ormal body habitus, and the ability to lie still and perform
reath-holding maneuvers.
It is unknown whether contemporary revascularization
herapy improves outcomes of LT candidates (50). How-
ver, revascularization should be considered in carefully
elected patients when the lack of revascularization is
eemed to present a prohibitive risk for LT. Therefore,
hen possible, it is important make an assessment of CAD
isk in the ESLD patient before revascularization becomes
ontraindicated (usually an excessive bleeding risk due to
oagulopathy and/or thrombocytopenia).
eart Failure and Cardiomyopathy
irrhosis is associated with a high cardiac output, increased
eft ventricular wall thickness, cardiac chamber enlargement,
nd significantly impaired systolic and diastolic response to
tress, especially in the setting of volume overload. The
egree of left ventricular hypertrophy seen on pre-operative
ristics Recommendations
CAD
get
ascular
Consideration of invasive or CT coronary angiography if known CAD,
abnormal noninvasive test or a high pre-test probability of CAD
(DM or 2 traditional risk factors)†
Cardiomyopathy/heart failure
Pre-operative TTE to assess systolic and diastolic cardiac function,
valves, and left ventricular outflow tract obstruction if LVH;
treatment of HF and LVOTO as appropriate
y
PAP
f
Pulmonary heart disease: TTE to assess for pulmonary hypertension,
with referral to RHC if elevated PASP or RV systolic dysfunction
found on TTE (to differentiate pulmonary venous and pulmonary
arterial hypertension) RHC to assess response to medical therapy
of confirmed POPH
ponade
s
Pericardial disease: TTE to assess for pericardial fluid and signs of
tamponade
ex Arrhythmia: electrocardiogram to assess baseline QTc interval;
treat reversible causes of long QTc
Intracardiac shunts: TTE to assess for PFO and other intracardiac
shunts; precaution against venous air emboli during transplant
procedure
ates (using coronary angiography as the gold standard): positive/negative predictive values for
% (Donovan et al. [36]), 0%/86% (Williams et al. [35]). Positive/negative predictive values for
]), 15%/100% (Aydinalp et al. [39]). †Traditional risk factors for CAD include age (male 45
AD (first-degree relative male 55 years/female 65 years).
ricular hypertrophy; LVOTO  left ventricular outflow tract obstruction; NPV  negative predictive
ry capillary wedge pressure; PFO  patent foramen ovale; POPH  portopulmonary hypertension;
 right ventricular; SVR  systemic vascular resistance; TTE  transthoracic echocardiography.ment
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load, suggesting a component of intrinsic subclinical cardio-
myopathy in LT candidates (termed cirrhotic cardiomyop-
athy) (51).
Cirrhotic cardiomyopathy, however, has been shown to
nvolve more than just left ventricular hypertrophy (52). It
ppears to be a complex condition that is also characterized
y a diminished contractile responsiveness to stress, im-
aired diastolic relaxation, and electrophysiological abnor-
alities, all in the absence of known cardiac disease. The
lunted cardiac response to stress is thought to be due to
utonomic dysfunction, together with impaired barorecep-
or and volume reflexes. Animal models of cirrhosis have
emonstrated both a decrease in beta-adrenoceptor density
s well as decreased beta-adrenoceptor–stimulated cyclic-
denosine monophosphate production (53). Diastolic dys-
unction is likely related to increased ventricular stiffness in
he setting of left ventricular hypertrophy (as noted above),
s well as impaired myocardial relaxation, possibly related to
bnormalities in calcium exchange through the sarcoplasmic
eticulum (54). The electrophysiologic abnormalities found
n cirrhotic cardiomyopathy include QT-interval prolonga-
ion, electrical and mechanical dyssynchrony, and chrono-
ropic incompetence (55–57).
The clinical ramifications of cirrhotic cardiomyopathy
ay not manifest until normal vascular tone is restored
ost-operatively. Thereafter, patients may be at risk of
aving acute decompensated heart failure develop in certain
ituations (58–60). In a retrospective study of 86 LT
ecipients who underwent both TTE and right-side heart
atheterization pre-operatively, new systolic heart failure
as significantly more likely to develop post-operatively
mong patients with elevated pulmonary artery or right-
eart pressures pre-operatively (61). Elevated pulmonary
ressures and post-operative myocardial depression can be
etrimental in LT patients, given their underlying cardio-
yopathic physiology, and have the potential to cause
ignificant cardiovascular complications. Both survivors and
onsurvivors of LT exhibit early myocardial depression,
ith nonsurvivors showing less cardiac reserve pre-
peratively and a very early drop in cardiac index and oxygen
elivery post-operatively. Very early cardiac depression
within 12 h) after transplant is associated with subsequent
ultiorgan failure and death (62).
A pre-operative TTE should be performed routinely for
he assessment of left ventricular, right ventricular, and
alvular function. Pre-transplant heart failure, regardless of
nderlying left ventricular ejection fraction, may resolve
ost-operatively in LT patients (63). Thus, the presence of
re-operative left ventricular dysfunction is not an absolute
ontraindication to LT, but is a risk factor for perioperative
ardiovascular complications. Successful LT in patients with
jection fraction as low as 10% has been reported with
ggressive medical management (64). Volume status and
ymptoms of heart failure should be monitored and opti-
ized before transplantations. A high index of suspicion ohould always be maintained for post-LT heart failure,
specially when a patient exhibits signs and symptoms
onsistent with volume overload including weight gain,
levated jugular venous pressure, crackles on lung examina-
ion, dyspnea, orthopnea, and increased lower extremity
dema.
Optimal medical therapy for heart failure in the setting of
eft ventricular systolic dysfunction, including beta-blockers,
ngiotensin-converting enzyme inhibitors, and aldosterone-
locking agents should be maintained in the perioperative
eriod, unless there is a contraindication to therapy such as
ypotension or renal failure (65). The renal toxicity of
alcineurin inhibitors can limit the use of angiotensin-
onverting enzyme inhibitors and aldosterone-blocking
gents in LT recipients. Carvedilol may be the optimal
hoice for beta-blockade in patients with ESLD. It has been
emonstrated to cause a reduction in portal pressure
hrough decreased splanchnic blood flow and decreased
ortocollateral resistance (66,67). Carvedilol has also been
hown to be superior to other beta-blocking agents in
educing the hepatic venous pressure gradient (66,68).
The assessment for left ventricular outflow tract obstruc-
ion (LVOTO) by TTE is an important component of the
re-operative cardiovascular assessment of LT candidates
ith left ventricular hypertrophy. Left ventricular hypertro-
hy and hyperdynamic systolic function in ESLD may
esult in hemodynamically significant LVOTO. One retro-
pective review of 106 transplant recipients found inducible
VOTO on pre-operative DSE in 40% of patients (69).
n this study, an outflow gradient of 36 mm Hg was
ignificantly associated with intraoperative hypotension. Al-
hough there was no significant mortality risk associated
ith LVOTO in this study, this condition has led to the
enial of transplantation at certain centers (69). Patients
ith LVOTO can exhibit poor tolerance of the hemody-
amic stresses associated with ESLD and transplantation.
areful intraoperative monitoring, however, with avoidance
f tachycardia, limited use of inotropic agents, and trans-
sophageal echocardiography-guided volume administra-
ion can facilitate safe transplantation in patients with
ignificant LVOTO (70–72). Patients with LVOTO due to
nderlying hypertrophic cardiomyopathy who also have
SLD can be considered for alcohol septal ablation if they
ave symptomatic heart failure that would otherwise con-
raindicate LT (73,74).
ulmonary Heart Disease
nd-stage liver disease has a causal role in 2 main pulmo-
ary syndromes: hepatopulmonary syndrome (HPS) and
ortopulmonary hypertension (POPH). Hepatopulmonary
yndrome is characterized by abnormal intrapulmonary
ascular dilation in patients with liver disease, leading to
hysiologic shunting, ventilation-perfusion mismatch, and
ypoxemia (75). Patients with HPS typically have normal or
nly mildly elevated pulmonary artery pressures, and LT
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hypertension with increased pulmonary vascular resistance
due to vasoconstriction and progressive pulmonary vascular
remodeling. Patients with this condition by definition have
concomitant portal hypertension (75). In POPH, as op-
osed to HPS, hypoxemia occurs late and LT is often
ontraindicated if it is left untreated. POPH is present in
pproximately 5% to 10% of LT candidates (76). Roughly
% of LT candidates have moderate to severe POPH, with
mean pulmonary arterial pressure (mPAP) 35 mm Hg,
hich has traditionally been considered a contraindication
o LT. A pre-operative mPAP of 35 to 50 mm Hg has been
ssociated with a 50% risk of mortality after LT in patients
ith POPH (77). In 1 study, mortality approached 100%
mong patients with POPH and mPAP 50 mm Hg (78).
he accurate diagnosis of POPH, therefore, is a crucial part
f the selection and perioperative management of LT
andidates. POPH can present a diagnostic challenge in
SLD; pulmonary artery systolic pressure on TTE may be
levated for many reasons aside from POPH, including
ulmonary venous hypertension from left ventricular dys-
unction, volume overload, or increased cardiac output.
Pulmonary artery systolic pressure should first be evalu-
ted by TTE in all LT candidates. If pulmonary artery
ystolic pressure is elevated or if there is right ventricular
ysfunction, right-side heart catheterization should be per-
ormed. If the mPAP is 35 mm Hg, but the pulmonary
apillary wedge pressure is high (15 mm Hg), repeat
ight-side heart catheterization should be performed after
iuresis. If the mPAP is 35 mm Hg and the pulmonary
ascular resistance is 3 Wood units in the setting of a
ulmonary capillary wedge pressure of 15 mm Hg, clinically
ignificant pulmonary arterial hypertension is present. In the
bsence of underlying lung disease (or other risk factors for
ulmonary arterial hypertension) in a patient with ESLD, this
hould be considered moderate to severe POPH.
Mild POPH (mPAP 25 to 34 mm Hg) is not an absolute
ontraindication for LT, especially if right ventricular func-
ion is preserved. However, moderate to severe POPH
mPAP 35 mm Hg) warrants consideration for treatment
ith pulmonary vasodilators before transplantation. Recent
ase reports and series have demonstrated that pharmaco-
ogical therapy for moderate to severe POPH (i.e., prosta-
oids, phosphodiesterase inhibitors, endothelin-receptor
ntagonists, and so forth) can lower pulmonary pressures to
afely facilitate LT (79–82).
ericardial Effusions
ericardial effusions resulting in cardiac tamponade can
evelop in ESLD patients and are associated with hepatitis
infection and cryoglobulinemia. Pericardial effusions have
lso been associated with ascites, a condition known as
epatohydropericardium, and can occur after LT (83–86).
n assessment for pericardial fluid and tamponade physi-
logy is an important part of the pre-operative TTE in LT uandidates. It has been observed that the sensitivity of TTE
o detect tamponade in the setting of portopulmonary
ypertension may be decreased. This is mainly due to the
ossibility of elevated right-sided pressures delaying or
educing right ventricular collapse, despite the underlying
xistence of tamponade physiology (87). Therefore, in
ddition to echocardiographic findings, it is important to do
complete bedside assessment and physical examination to
ccurately diagnose tamponade in ESLD patients. The
resence of a significant pericardial effusion or tamponade
hould be treated by pericardiocentesis or a pericardial
indow before or at the time of LT. Because the causes of
hese effusions are often related to the underlying ESLD,
T candidates require close clinical and echocardiographic
ollow-up for recurrence.
atent Foramen Ovale
patent foramen ovale (PFO) is present in approximately
5% of adults in the general population and is associated
ith paradoxical embolism (88,89). There are case reports
f iatrogenic venous air embolism, with right-to-left shunt-
ng of emboli across a PFO during LT (90,91). The overall
ncidence of this complication appears to be quite low
isolated case reports), and liver transplantation for the most
art can be performed safely in patients with a PFO and
ther types of intracardiac shunts (92). Although the pres-
nce of a PFO is not a contraindication to LT, extra care
hould be taken to prevent thrombus formation and air
ntry into the venous system during surgery. Further studies
re needed to determine the ultimate clinical significance of
he presence of a PFO during LT and the potential role, if
ny, for percutaneous PFO closure in LT candidates.
T Interval Prolongation
he presence of a prolonged corrected QT interval (QTc)
n an electrocardiogram (440 ms) can be associated with
n increased risk of ventricular arrhythmias. Although QTc
rolongation is common in patients with ESLD, it often
esolves after transplantation (93,94). In a retrospective
ohort, nearly one-half of 600 ESLD patients studied had a
Tc 440 ms pre-operatively, with resolution in approxi-
ately one-half of these patients after transplantation.
dvanced age, alcoholic cirrhosis, and Childs class were
ndependent predictors of prolonged QTc. There was,
owever, no association between prolonged QTc and in-
reased mortality (95). Of note, the physiologic differences
n QTc between males and females are abolished in cirrhosis
decreased impact of estrogen/sex-specific hormone levels
n QT interval physiology in these patients) (96). A
rolonged QTc is not a contraindication to LT, but should
rompt a search for reversible causes, such as electrolyte
isturbance (e.g., hypokalemia or hypomagnesemia) or the
se of QT interval-prolonging drugs.
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The recommendations in the preceding text apply specifi-
cally to patients with ESLD from chronic hepatic failure.
Patients who require LT because of acute hepatic failure
have underlying cardiac and physiologic states that differ
from patients who have chronic liver disease, and should
thus be risk stratified accordingly (97). In most cases, the
pre-transplant cardiac risk stratification for these patients
can be done in a fashion similar to that for other noncardiac
surgeries. Two of the most commonly used algorithms for
estimating cardiac risk before surgery are the 2007 Ameri-
can College of Cardiology/American Heart Association
guidelines and the Goldman revised cardiac risk index
(98,99). These methods differ in their approach, but their
emphasis is on defining the urgency of surgery (which may
supersede risk stratification), determining the presence of
high-risk conditions that could delay surgery, and making
further recommendations based on functional status and
other clinical risk factors.
All patients with acute hepatic failure being evaluated for
LT should undergo TTE to assess left and right ventricular
function, valvular function, and to identify any significant
pulmonary hypertension (the etiology of which would likely
be independent of acute liver failure). Given the extensive
fluid shifts and hemodynamic stresses associated with LT,
patients with ventricular dysfunction should be closely
monitored for volume overload in the perioperative period
(e.g., with Swan-Ganz catheter for pressure/hemodynamic
monitoring). Furthermore, patients with pulmonary hyperten-
Figure 1 Suggested Strategy for Pre-Operative Cardiac Assess
CAD  coronary artery disease; CTA  computed tomography angiogram; ECG  e
outflow tract obstruction; POPH  portopulmonary hypertension; Pulm.  pulmona
echocardiography.sion in the setting of elevated pulmonary capillary wedge
pressures (pulmonary venous hypertension) should undergo
diuresis before surgery. Patients with pulmonary arterial hy-
pertension should ideally undergo a trial of medical therapy
before any surgical intervention (similar to patients with
chronic liver disease and pulmonary arterial hypertension).
Recommendations
The American College of Cardiology and the American
Heart Association do not provide specific recommenda-
tions for the pre-operative cardiovascular assessment of
LT candidates. The American Association for the Study
of Liver Diseases recommends an evaluation for CAD in
LT candidates who are chronic smokers, have a personal
or family history of CAD, or have DM (100). These
guidelines recommend DSE followed by coronary an-
giography when appropriate. Because of the already
discussed limitations of pharmacologic stress testing in
LT candidates, we do not recommend routine noninva-
sive stress imaging (Table 1). In patients with known
CAD, DM, or 2 other cardiovascular risk factors, we
recommend coronary angiography to assess the extent
and severity of CAD. Cardiac CT angiography may be an
acceptable alternative in select patients. Coronary revas-
cularization should be considered in LT candidates with
obstructive CAD if the extent of CAD contraindicates
transplantation. The bleeding risk for any procedure
should be taken into consideration. For patients under-
going percutaneous coronary intervention, bare-metal
of Liver Transplant Candidates
cardiogram; HF  heart failure; LV  left ventricular; LVOTO  left ventricular
c  corrected QT interval; RV  right ventricular; TTE  transthoracicment
lectro
ry; QT
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bleeding from the prolonged duration of dual antiplatelet
therapy required for drug-eluting stents.
The American Association for the Study of Liver Dis-
eases recommends TTE with Doppler for all LT candi-
dates. Echocardiography is necessary to assess left and right
ventricular size and function, valvular function, and pulmo-
nary artery pressure, and to exclude the presence of a
significant LVOTO or pericardial effusion. Mild-to-
moderate heart failure is not an absolute contraindication to
LT, but should be monitored and aggressively treated in the
perioperative period. There are currently no guidelines for
the management of LT candidates with significant
LVOTO. Transesophageal echocardiography and/or pul-
monary artery catheterization may be used intraoperatively
to allow for real-time hemodynamic monitoring and volume
management.
Patients with elevated pulmonary arterial systolic pressure
on TTE or right ventricular systolic dysfunction should be
referred for right-side heart catheterization. Elevated pul-
monary artery pressure alone should not be a contraindica-
tion to transplantation; rather, a careful evaluation of
invasive hemodynamics should be used to identify patients
who simply have volume overload and/or high-output state,
in which case pulmonary vascular resistance is typically
normal. Patients with moderate to severe POPH (POPH
with mPAP 35 mm Hg and elevated pulmonary vascular
resistance) should be referred to a cardiologist or pul-
monologist with expertise in the administration of pulmo-
nary vasodilator therapy. After a trial of vasodilator therapy,
right-side heart catheterization should be repeated before
proceeding with LT. If the decision is made to proceed with
LT in a patient with significant POPH (medical therapy
responders), transesophageal echocardiography to monitor
for right ventricular dysfunction, venovenous bypass to
prevent sudden right ventricular overload after reperfusion,
and use of inhaled nitric oxide therapy to lower pulmonary
artery pressures are intraoperative strategies to minimize the
risk of cardiogenic shock due to fulminant right ventricular
failure after LT.
Any significant pericardial effusion should be treated by
either pericardiocentesis or a pericardial window before or at
the time of LT. In addition, the presence of a PFO is not a
contraindication to LT, but extra care should be taken to
avoid air entry into the venous system or thrombus forma-
tion during the transplant procedure. Finally, reversible
causes of electrocardiographic QTc prolongation should be
addressed before LT.
These recommendations (Fig. 1) are based upon the
available body of evidence regarding the diagnosis and
treatment of cardiovascular disease in patients with ESLD.
There is still a significant knowledge gap in the study of
cardiovascular outcomes, including quality-of-life out-
comes, in patients undergoing LT. The unique physiol-
ogy of ESLD can profoundly influence accurate diagno-
sis, management, and outcomes of underlying cardiacpathology, and requires a careful evidence-based ap-
proach to the perioperative cardiovascular management
of LT candidates.
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